These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 20160706)
1. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706 [TBL] [Abstract][Full Text] [Related]
2. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses. Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405 [TBL] [Abstract][Full Text] [Related]
3. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246 [TBL] [Abstract][Full Text] [Related]
4. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Breitbach CJ; Thorne SH; Bell JC; Kirn DH Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365 [TBL] [Abstract][Full Text] [Related]
5. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Hu J; Wang H; Gu J; Liu X; Zhou X Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492 [TBL] [Abstract][Full Text] [Related]
7. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794 [TBL] [Abstract][Full Text] [Related]
8. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Kirn DH; Thorne SH Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Wang J; Hu P; Zeng M; Rabkin SD; Liu R Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767 [TBL] [Abstract][Full Text] [Related]
11. Replicating poxviruses for human cancer therapy. Kim M J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536 [TBL] [Abstract][Full Text] [Related]
12. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity. Cuddington BP; Mossman KL J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490 [TBL] [Abstract][Full Text] [Related]
13. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776 [TBL] [Abstract][Full Text] [Related]
14. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Sathaiah M; Thirunavukkarasu P; O'Malley ME; Kavanagh MA; Ravindranathan R; Austin F; Guo ZS; Bartlett DL Cancer Gene Ther; 2012 Mar; 19(3):192-201. PubMed ID: 22116377 [TBL] [Abstract][Full Text] [Related]
16. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. Gentschev I; Donat U; Hofmann E; Weibel S; Adelfinger M; Raab V; Heisig M; Chen N; Yu YA; Stritzker J; Szalay AA J Biomed Biotechnol; 2010; 2010():489759. PubMed ID: 20379368 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143 [TBL] [Abstract][Full Text] [Related]
18. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
19. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]